中国再生医学(08158.HK)3,500万售旗下部份销售业务
中国再生医学(08158.HK)公布,直接全资附属中国生物医学再生科技,以3,500万元出售中国再生医学组织工程和中国再生医院投资管理股份,两间出售公司均处於亏损状态,估计出售事项收益约460万元。
股份包括两集团,其中中国再生医学组织工程主要从事生产及销售皮肤科产品及服务、买卖医疗设备、生产及销售口腔科产品及其他;中国再生医院投资管理主要从事生产及销售眼科产品。
公司预期所得款项净额为3,400万元,其中600万会用於员工成本;1,500万用於研发;1,300万用於广告、营销及推广开支。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.